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The capacity of morphine to suppress natural and precipitated 
withdrawal was compared in morphine-dependent rhesus monkeys. A 
similar severity of withdrawal was induced by 14-hr deprivation or 
precipitated by naloxone, naltrexone, cyclazocine, Win 44,441 or MR 
2266. Regardless of the procedure used to induce withdrawal, behav- 
ioral signs were completely suppressed by a cumulative dose of 17.5 
q glkg morphine. Thus, an equivalent level of withdrawal induced by 
reversible antagonists is as sensitive to subsequent morphine admin- 
istration as is deprivation-induced abstinence. This is in accord- 
ance with the theory that vacancy of opiate receptors normally 
occupied by morphine is related to the level of abstinence observed. 
In contrast to Win 44,441, however, an equivalent level of withdrawal 
precipitated by buprenorphine required 175 mg/kg morphine for comp- 
lete suppression. This is more informative than comparing duration 
of action; when given as 24-h pretreatments, a high dose of Win 
44,441 (10 mg/kg) was only slightly less effective than buprenorphine 
(3.2 mg/kg) in antagonizing morphine-induced stupor in normal mon- 
keys. Comparison of the ability of morphine to suppress precipitated 
withdrawal provides evidence of the relative reversibility of antag- 
onists in vivo and demonstrates the extraordinarily stable nature by 
which buprenorphine acts at opiate receptors. 
INTRODUCTION 
Narcotic antagonists have been extremely important historically in terms 
of the identification of opiate receptors, investigations of the homeostatic 
role of endogenous opioids, generally as tools in all areas of opiate research, 
and of course, clinically. Interest in antagonists has been further heightened 
by the introduction of long-lasting narcotic antagonists in opiate-addiction 
therapy [l], and the synthesis of opiate receptor alkylators such as beta-chlor- 
naltrexamine [2]. This laboratory has been investigating various properties of 
opiate antagonists using behavioral preparations. In the present study, the 




Subjects Group housed monkeys trained to receive injections were tested 
weekly. Their overt behavior was monitored continuously throughout the test 
sessions by two experienced observers familiar with the individual animals. 
General muscle relaxation and stupor grades were given according to the des- 
criptions in Table 1. Monkeys were made dependent by administering morphine 
sulfate (3 mg/kg, s.c.) every 6 h for at least 3 months. Higher withdrawal 
severity grades were given with an increase in the number and severity of 
withdrawal signs [3]. Suppression of withdrawal was tested starting 14 h after 
the last maintenance dose of morphine (deprivation-induced withdrawal), 0.5 h 
after naloxone or 1 h after buprenorphine, cyclazocine, MR 2266 ((-)-5,9-dieth- 
yl-2-(3-furylme,thyl)-Z'-hydroxy-6,7-benzomorphan), naltrexone and Win 44,441 
((2~,601,11S)-(-)-1-cyclopentyl-5-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,ll-trine- 
thyl-2,6,-methano-3-benzozocin-ll-yl)-3-pentanone methanesulfonate) (precipit- 
ated withdrawal). Morphine was given cumulatively every 30 min such that the 
dose increased by 4 or e-log units. 
TABLE 1 
Scales by which monkeys were graded for general muscle relaxation 
(according to the position animals take while sitting still) and 
stupor (according to the animals' response to external stimuli). 
Grade Muscle Relaxation 
0 No observable muscle relaxation 
1 Slight facial relaxation, jaw slackening, shoulder droop 
2 Pronounced facial relaxation, jaw slackening, shoulder droop 
3 Monkey must brace himself to sit up 
4 Monkey cannot sit 
Grade Stupor 
NOS No observable stupor 
+ Monkey appears to stare into space 
A Monkey is inattentive to ordinary movements of other monkeys 
A+ Monkey is inattentive to ordinary movements of observers 
B Must gain attention of monkey by loud noises 
B+ Monkey responds only to opening of cage latch 
C Monkey responds only to loud noises by his ear 
c+ Monkey responds only to touch 
RESULTS 
Normal Monkeys The duration of action of selected opiate antagonists were 
examined in drug-naive monkeys. Morphine (l-100 mg/kg) caused a dose-related 
increase in the number of monkeys showing higher levels of stupor and muscle 
relaxation. The effects of cumulative morphine were antagonized by 1 h pre- 
treatment with naltrexone (1 mg/kg) or Win 44,441 (1 mgjkg). Morphine-induced 
stupor was also antagonized by 24-h pretreatment with Win 44,441 (10 mg/kg) or 
buprenorphine (3.2 mg/kg) as shown in Fig. 1; morphine-induced muscle relaxa- 
tion was similarly antagonized. Twenty-four h pretreatment with naltrexone (10 
mgikg) did not antagonize the observable effects of cumulative morphine. 
Dependent Monkeys An equivalent level of withdrawal (severity scores of 
3.5-4.5) was observed during 14-h deprivation and after the administration of 
naltrexone (0.01 mg/kg), naloxone (0.03 mgfkg), cyclazocine (0.03 mg/kg), Win 
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44,441 (0.03 mg/kg) and MB 2266 (0.056 mg/kg) (Fig. 2). Withdrawal was complet- 
ely suppressed by a cumulative dose of 17.5 mglkg morphine. However, the same 
level of withdrawal precipitated by buprenorphine (0.3 mg/kg) required 175 
mg/kg morphine for complete suppression. 
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Figure 1: The effect of morphine 
given every 30 min to normal rhesus 
monkeys (n=6) on stupor in the 
absence of antagonist (solid lines), 
and 24 h after pretreatment with Win 
44,441 (10 mg/kg; dashed lines) or 
buprenorphine (3.2 mg/kg; dotted 
1 ines) . Each horizontal segment 
represents the percent of monkeys 
(from 0 to 100%) showing that 
particular level of effect 
indicated, as defined in Table 1. 
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Figure 2: Morphine suppression of 
14-h deprivation-induced abstinence 
( 0 ) and withdrawal precipitated by 
naloxone ( A ), naltrexone ( 0 >, MR 
2266 ( V ), cyclazocine ( V ), Win 
44,441 ( 0 ) and buprenorphine ( n ) 
in morphine-dependent rhesus monkeys 
(mean of 6). P.I.= pre-injection; 
Ant. = antagonist administration. 
DISCUSSION 
The dose of antagonist given to dependent monkeys can be adjusted such 
that the resulting withdrawal is of equivalent severity to that produced by a 
period of abstinence from morphine. Furthermore, there are no observable 
differences in the behavior of monkeys undergoing precipitated and deprivation- 
induced withdrawal. Given that the severity of effect is equivalent, depriva- 
tion-induced and precipitated abstinence is suppressed by equal amounts of 
morphine. This suggests that equivalent withdrawal is produced by the 
equivalent mechanisms, whether due to deprivation or antagonist administration, 
and extends the notion [41 that opiate receptor occupancy (i.e., the fraction 
of receptors no longer occupied by morphine) is related to the level of with- 
drawal observed. 
Buprenorphine is a very lipophilic agonist-antagonist which dissociates 
extremely slowly from opiate receptors. Hambrook and Bance [5] suggested that 
this property accounts for the long duration of action of this compound and its 
relative resistance to antagonism. Whereas Win 44,441 and buprenorphine both 
have long durations of action in reversing morphine, ten times more morphine 
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was required to reverse the established antagonist effect of buprenorphine than 
Win 44,441 (above). Similarly, Cowan et al. [6] found that significantly 
higher doses of diprenorphine were required to reverse, rather than prevent, 
agonist effects of buprenorphine in the rat. These studies demonstrate the 
extraordinary stability of the buprenorphine-receptor complex. The fact that 
buprenorphine-induced withdrawal could be reversed by subsequent morphine 
administration, however, indicates that buprenorphine is not absolutely insur- 
mountable in this system, whereas beta-funaltrexamine-induced withdrawal, for 
example, cannot be reversed by morphine 171. Suppression of withdrawal is a 
useful and simple procedure for the in vivo estimation of the reversibility of 
antagonists. 
In summary, the results indicate that (a) abstinence severity is related 
to the vacancy of opiate receptors normally occupied by morphine and (b) the 
suppression of withdrawal by morphine provides information as to the relative 
reversibility of opiate antagonists. 
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